The Rest Of Asia Pacific Dental Soft-Tissue Regeneration Market was valued at $7.4 Million in 2024 and projected to reach to $11.51 Million by 2029, representing a compound annual growth rate of 9.2%. The Rest Of Asia Pacific dental soft-tissue regeneration market is poised for sustained growth through 2029, driven by increasing healthcare investments and rising patient awareness of advanced regenerative treatments.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Asia Pacific's dental soft-tissue regeneration market is expanding at 9.2% CAGR, significantly outpacing the global growth rate of 7.8%, indicating strong regional momentum and market maturation.
The market is valued at USD 7.4 million in 2024 with a projected CAGR-driven expansion to USD 11.51 million by 2029, representing a 55.5% increase over the five-year forecast period.
Increasing adoption of advanced regenerative therapies across Rest Of Asia Pacific is driving market expansion, reflecting growing awareness among dental practitioners and patient demand for innovative soft-tissue solutions.
Rest Of Asia Pacific represents a high-growth emerging market segment with untapped potential, driven by improving healthcare infrastructure, rising disposable incomes, and expanding dental care accessibility in developing nations.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | PERIODONTOLOGY (Application) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 7.8% from 2024 to 2029 |
| Largest Segment | AUTOGRAFTS (Product Type) |
| Market Size Base Year (Billions) | ~USD 0.34 (2024) |
| Revenue Forecast (Billions) | ~USD 0.54 (2029) |
| Segments Covered | Product Type, Application, End User |
3 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| HENRY SCHEIN, INC. | United States | Public Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| ENVISTA | United States | Public Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| ZIMVIE INC. | United States | Private Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| DENTSPLY SIRONA INC. | United States | Public Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| ABBVIE INC. | United States | Public Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| ADVANCED MEDICAL SOLUTIONS GROUP PLC | United Kingdom | Public Company | Collagen-based Membranes,Synthetic Biomaterials,Autografts, |
| TISSUE REGENIX | United Kingdom | Private Company | Autografts,Synthetic Biomaterials,Collagen-based Membranes, |
| MECCELLIS BIOTECH | France | Collagen-based Membranes,Synthetic Biomaterials,Autografts, |
Henry Schein, Inc. is a publicly traded American company founded in 1932 with approximately 25,000 employees. It is a leading global distributor of dental, medical, and veterinary products and services.
Envista is a publicly traded American company founded in 2018 with approximately 12,000 employees. The company operates as a global provider of dental products, technologies, and services.
Zimvie Inc. is a privately held American company founded in 2021 with approximately 1,770 employees. The company focuses on dental implants, bone regeneration, and related surgical solutions.
Dentsply Sirona Inc. is a publicly traded American company founded in 2015. The company is a leading manufacturer and distributor of dental products, technologies, and equipment.
AbbVie Inc. is a publicly traded American pharmaceutical company founded in 2012 with approximately 57,000 employees. The company develops and markets a broad range of pharmaceutical products across multiple therapeutic areas.
Advanced Medical Solutions Group PLC is a publicly traded British company founded in 1991 with approximately 1,800 employees. The company specializes in advanced wound care and surgical solutions.
Tissue Regenix is a privately held British company founded in 2006 with approximately 92 employees. The company develops regenerative medicine and advanced wound care products.
Meccellis Biotech is a French company founded in 2011 that operates in the biotechnology sector. The company focuses on regenerative medicine and cellular therapy solutions.
Rest Of Asia Pacific's dental soft-tissue regeneration market was valued at USD 7.4 million in 2024.
Rest Of Asia Pacific's market is forecasted to reach USD 11.51 million by 2029.
Rest Of Asia Pacific's market is expected to grow at a compound annual growth rate of 9.2% from 2024 to 2029.
Rest Of Asia Pacific's growth is driven by increased dental healthcare awareness, rising adoption of regenerative therapies, expanding clinical applications, and growing healthcare expenditure in emerging economies.
Rest Of Asia Pacific's market includes established multinational dental companies and innovative regional manufacturers developing localized regenerative dental solutions.
This study involved four key activities to estimate the current size of the dental soft-tissue regeneration market. First, extensive secondary research was conducted to gather information about the market, as well as related markets and the overall parent market. Next, the findings, assumptions, and estimates were validated through primary research conducted with industry experts across the value chain. Both top-down and bottom-up approaches were utilized to determine the overall market size. Finally, market breakdown and data triangulation techniques were employed to estimate the sizes of various segments and subsegments.
The secondary research process utilized a variety of sources, including directories and databases such as Bloomberg Business, Factiva, and D&B Hoovers, as well as white papers, annual reports, company documents, investor presentations, and SEC filings. This method was employed to gather information relevant to a comprehensive, technical, market-focused, and commercial analysis of the dental soft-tissue regeneration market. It also helped obtain crucial details about key players in the industry, market classification, and segmentation based on current trends, extending down to the most granular levels. Additionally, important developments related to market and technological perspectives were captured. A database of key industry leaders was created using the information collected through secondary research.
In the primary research process, a variety of sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. On the supply side, primary sources included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from important companies and organizations operating in the dental soft-tissue regeneration market. On the demand side, primary sources consisted of industry experts, purchasing and sales managers, doctors, and personnel from research organizations. This primary research aimed to validate market segmentation, identify key players, and collect insights on major industry trends and market dynamics.
A breakdown of the primary respondents for the dental soft-tissue regeneration market is provided below:
Note 1: C-level executives include CEOs, CFOs, COOs, and VPs.
Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global dental soft-tissue regeneration market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the global dental soft-tissue regeneration market was split into various segments and subsegments based on:
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After arriving at the overall size of the global dental soft-tissue regeneration market through the above-mentioned methodology, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Dental soft-tissue regeneration involves restoring or reconstructing soft tissues, including the gums and connective tissues surrounding the teeth. This process seeks to facilitate the healing of tissues lost due to gum disease or trauma to enhance the health and aesthetic appearance of the gums and their functionality. These procedures can be effectively used in the treatment of gum recession, tissue defects around the implants, or any other soft-tissue defects, and eventually, to improve the smile.
Full forecast, segment splits, and company analysis for all Dental Soft-Tissue Regeneration Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report